WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003061655) 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1 ADENOSINE RECEPTORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/061655    International Application No.:    PCT/US2003/001396
Publication Date: 31.07.2003 International Filing Date: 16.01.2003
Chapter 2 Demand Filed:    18.08.2003    
IPC:
C07D 277/60 (2006.01), C07D 277/84 (2006.01)
Applicants: UNIVERSITY OF VIRGINIA PATENT FOUNDATION [US/US]; Suite I-110, 1224 West Main Street, Charlottesville, VA 22903 (US) (For All Designated States Except US).
LINDEN, Joel [US/US]; (US) (For US Only).
MURPHREE, Lauren [US/US]; (US) (For US Only).
CHORDIA, Mahendra, D. [IN/US]; (US) (For US Only).
MACDONALD, Timothy, L. [US/US]; (US) (For US Only)
Inventors: LINDEN, Joel; (US).
MURPHREE, Lauren; (US).
CHORDIA, Mahendra, D.; (US).
MACDONALD, Timothy, L.; (US)
Agent: WRIGHT, Bryan, D.; Williams Mullen, 401 East Market Street, Suite 101, Charlottesville, VA 22902 (US)
Priority Data:
60/349,191 16.01.2002 US
Title (EN) 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1 ADENOSINE RECEPTORS
(FR) ACTIVATEURS ALLOSTERIQUES 2-AMINOTHIAZOLES DES RECEPTEURS DE L'ADENOSINE A1
Abstract: front page image
(EN)The present invention relates generally to a class of 2-aminothiazole derivatives which have recently been identified as allosteric enhancers of the A1 adenosine receptor. These compounds, and therapeutic compositions containing them, are useful for treating conditions in which activation of the A1 adenosine receptor would be beneficial, for example, those conditions in which stimulation of angiogenesis would improve blood flow to ischemic tissues.
(FR)La présente invention concerne une classe de dérivés de 2-aminothiazoles récemment identifiés comme activateurs allostériques du récepteur de l'adénosine A1. Ces composés et les compositions thérapeutiques les contenant permettent de traiter les états pour lesquels l'activation du récepteur de l'adénosine A1 serait bénéfique, par exemple, les états pour lesquels la stimulation de l'angiogénèse améliorerait le débit sanguin vers les tissus ischémiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)